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ABSTRACT 
Novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused more than 2,38 million deaths and more than 108 
million cases confirmed in one year of the pandemic are massive upheavals in social life and economy in the international world. An effective vaccine is 
needed to prevent further morbidity and mortality. This research aims to identify the challenge in implementing mass vaccination in Indonesia which is 
related to the efficacy of the COVID-19 vaccine. We retrieve sources from relevant and published articles in Google Scholar, Pubmed, DOAJ and Science 
Direct of articles up to January 2021. The keywords used for gathering information were listed below. Vaccine efficacy is defined as the proportional 
reduction of a disease case in a group of vaccinated participants compared with unvaccinated participants. The study of vaccine efficacy is a cohort study 
that is an important vaccine trial method in the field. It is conducted randomly on a large scale by using a control-placebo. During the trials, the country 
which used the vaccine needs to maintain and observe the vaccine epidemiology. A trial roadmap is expected to identify the condition of the area 
epidemiologically. Vaccine efficacy is essential to be observed before implementing the vaccine in society. However, intensive socialization about the 
advantage of vaccines is mainly needed to prevent irrelevant information in social media about mass vaccination.  
Keywords: Efficacy, Covid-19 vaccine, Mass vaccination, Challenge 
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/) 
DOI: https://dx.doi.org/10.22159/ijap.2021v13i4.41270. Journal homepage: https://innovareacademics.in/journals/index.php/ijap  
Speedy peer review was done as the subject of the manuscript was related with pandemic. 
 
INTRODUCTION 
Novel coronavirus 2019 has been identified as the new infectious 
disease that appeared for the first time in December 2019 in China 
[1]. World Health Organization (WHO) states that this virus was a 
novel coronavirus 2019 (2019-nCoV) [2]. In February 2020, WHO 
announced that the name of the new disease is Coronavirus Disease 
(COVID-19) which was caused by Severe Acute Respiratory Syndrome 
Coronavirus-2 (SARS-CoV-2) [3]. As WHO has stated that COVID-19 
is a global pandemic, [4] an effective vaccine to prevent and control 
the pandemic is needed and required [5]. 
In this pandemic condition, society needs to understand and define 
various methods and strategies such as intensive socialization and 
continuous campaign before vaccine utilization in preventing COVID-19. 
It is about the importance of mass vaccination to prevent and control 
this pandemic. Besides, it is significantly important to pay attention in 
the last six months about disease condition, model and characteristic of 
transmission, the severity of disease, area transmission, susceptible 
group and society discipline in implementing a strict health protocol 
through 3M (keep the distance, wash the hands and use the mask) to 
control the disease optimally and measurably.  
Novel coronavirus, severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2), has caused more than 2,38 million deaths and more 
than 108 million confirmed cases in a one-year pandemic [6], and 
there are massive upheavals in social life and economy in the 
international world. The SARS-CoV-2 virus was transmitted between 
individuals, primarily through droplets or other possible ways [7]. 
The virus can be transmitted from people to people with or without 
experiencing any symptoms [8]. During the recovery time, the 
patient can excrete virus’ RNA for weeks [9, 10] and even can be 
longer in the immunosuppressed individuals [11]. 
Vaccine efficacy of COVID-19 is needed, at least, to prevent high 
severity caused by the infection of SARS-CoV-2. In order to gain this 
potential, well-maintained data collection is required to evaluate the 
cause of severe conditions and data on the disease severity. When 
the onset entered a hospital, it must be evaluated whether they need 
breathing apparatus or intensive handling from the current unit [12, 
13]. An effective vaccine is demanded to prevent further morbidity 
and mortality. After one year of the global pandemic by WHO, many 
vaccines have been injected into people globally, including 
Indonesia. Others are still developing preclinical and clinical phases 
by still referring to procedures and testing [14]. 
Definition and calculation of vaccine efficacy 
Along with vaccine development and testing, it is also necessary to 
have vaccine efficacy testing in society. Vaccine efficacy is defined as 
a proportional reduction of a disease case in a group of vaccinated 
participants compared with a group of unvaccinated participants 
(control-placebo) [13, 15]. The definition of efficacy in this context 
shows the vaccine ability in cohort research activities. The 
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Example 
Phase 4 of the vaccine trial, randomized placebo-control double-blind, 
was conducted using random allocation (1:1), involving 2000 
participants. 1000 participants were allocated as a vaccinated group, 
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and 1000 participants received a placebo. After 28 d, it has been 
identified that disease cases have occurred in 10 participants of the 
vaccinated group and 80 participants of the unvaccinated group. 
Applying the formula above shows that the percentage of disease 
cases in the vaccinated group is 0,01 or 1%, and the percentage of the 
placebo group is 0,08 or 8%. It means that vaccine efficacy is 87,5%. 
Method in vaccine efficacy studies 
This research is expected to be strictly based on the scientific 
method, regardless of global economic and political interests, so that 
the further implemented vaccine in each country has sufficiently 
high efficacy in protecting its society from infection. Some countries 
might have set a high standard for the implemented vaccine in terms 
of efficacy and safety. However, globally, the main purpose of 
vaccine development is to obtain direct evidence of vaccine efficacy 
in protecting humans from SARS-CoV-2 or COVID-19 infection [16].  
Efficacy studies must be pursued optimally to meet the efficacy 
targets and consider several variables, such as local transmission 
rate, participant’s characteristic, the severity of COVID-19, variation 
of mortality rated based on age, gender, ethnic and others [17]. 
Several efforts have been made to fulfill all steps in vaccine 
development until vaccine implementation in the field [18]. Vaccine 
efficacy studies is a cohort study using an essential method in a 
vaccine trial in the field. It is conducted randomly on a large scale by 
using control-placebo, and this is the crucial part to be used as a 
basis for making decisions and regulatory policies about the 
certainty of the safety and efficacy of the vaccine candidates [19]. 
COVID-19 vaccine development has occurred, where some vaccine 
candidates are in phase 3 in the clinical trial stage [20]. The report of 
large-scale randomized field vaccine trials has been stated by Baden et 
al.,[21] Phase 3 trial is conducted in randomize disguised, control-
placebo in 99 research centers involving 30,402 volunteers in the 
United States of America. A person with a high risk of contrasting 
SARS-CoV-2 or the complications is allocated randomly with a ratio of 
1:1 to get an intramuscular injection (IM) mRNA-1273 (100 μg) expect 
placebo [21]. The trial concluded that the COVID-19 vaccine mRNA-
1273 has 94,1% efficacy in preventing COVID-19, including severe 
disease. The steps of a vaccine trial in each area are not exactly the 
same, which depends on the fund availability, decision-maker 
commitment and policyholder, volunteer availability and other 
supporting factors. However, at least, the evidence is based on the 
testing phase, and it can be justified so that once the vaccine is 
implemented in society, it is truly safe and provides optimal protection 
against exposure to COVID-19. Apart from Baden et al., Logunov et al., 
2020 also has published the results of the efficacy and safety test of the 
Gam-COVID-Vac vaccine [22]. Phase 3 trial was held in 25 hospitals 
and polyclinic in Moscow (Russia) with a randomized, double-blind 
and placebo-controlled method. This trial involved 18 y old participant 
and went through PCR SARS-CoV-2 PCR negative as well as IgG and 
IgM. The examination showed no infectious disease 14 d before the 
trial and did not have another vaccination 30 d before the trial. 
Participants were allocated randomly in a 3:1 ratio to receive a vaccine 
or placebo stratified by age group. The vaccine was administered by 
0,5 ml/dose IM in the regimen prime-boost, with intervals of 21 d 
between the first and second doses. From that trial result, it is 
concluded that phase 3 in the vaccine trial, Gam-COVID-Vac has 91,6% 
efficacy in resisting COVID-19 and has great tolerance on a larger scale.  
Both Baden et al. and Logunov et al., in phase 3 vaccine trial have a 
similarity in process and methods, where the methodology of the trial 
is carried out under scientific principles with a cohort research design. 
In Indonesia, a clinical trial is carried out by using the Sinovac 
vaccine. The sinovac vaccine, which has 65,3% of efficacy, is 
declared safe. Although it has side effects, they are mild and 
reversible. The concern related to antibody-dependent enhancement 
(ADE), as many mentioned in social media and became society’s fear, 
did not occur in the Sinovac clinical trial in Indonesia or Turkey and 
Brazil [23]. 65,3% of efficacy in a clinical trial means a reduction for 
65,3% of disease cases in the vaccinated group compared to the 
unvaccinated group (placebo), and it was obtained in a controlled 
clinical trial. For example, clinical trial in Bandung, 800 subjects 
received the vaccine, and 800 subjects received a placebo (empty 
vaccine) among 1,600 participants. If in the vaccinated group, there 
are 26 infected subjects (3,25%), while in the placebo are 75 
subjects who are infected to COVID-19 (9,4%), so the vaccine 
efficacy is 0,094–0,0325)/0,094 x 100 % and the result is 65,3% 
[24]. It means that the ratio between vaccinated and unvaccinated 
groups become the defining factor. This efficacy will be affected by 
the test subject’s characteristics. If the test subject is a high-risk 
group, so the probability of the placebo group will have more 
infected subjects, the calculation of efficacy will increase. If the test 
subject is a low-risk group and more subjects stay at home and even 
apply the health protocol strictly, there may be fewer infected 
subjects in the placebo group. It has caused the comparison of 
infection cases between placebo and vaccinated groups, resulting in 
a lower vaccine efficacy rate.  
The efficacy result of the Sinovac vaccine was 65.3 percent, which 
might cause disappointment to some people, but this will be the first 
step where the agreement of minimum vaccine percentage from 
FDA, WHO and EMA is 50%. It defines that decreasing the infection 
case by 50 percent epidemiologically is meaningful and has saved 
many people’s lives.  
The role of policyholder in implementing mass vaccination 
Many vaccine candidates have entered the testing phase in several 
countries until phase 3, and some have even implemented it. (WHO, 
2020d) [20]. It shows that no vaccine may be excellent because of 
technology, but it depends on the epidemiological context in each 
implementation area [13]. 
Unlike the two developed countries mentioned above, the country 
does not produce the vaccine independently in implementing a 
vaccine in one’s country. Cooperation between countries is needed. 
In this condition, vaccine safety and efficacy have been done by 
vaccine producer countries. A user country also can conduct a vaccine 
efficacy trial, although on a limited basis. After that, the vaccine 
producer country conducts the trial. The user country keeps observing 
the vaccine epidemiology. The trial roadmap is expected to recognize 
the condition of the area epidemiologically during the trial.  
Challenge in implementing mass COVID-19 vaccination in 
Indonesia 
Other than safety and vaccine efficacy which is the attention before 
implementing mass vaccination, there are several principles to be 
fundamentally understood by decision-makers or policyholders in 
Indonesia. Some challenges need to be noticed in implementing 
mass COVID-19 vaccination in Indonesia, such as determining the 
priority scale of groups to be vaccinated in the first place, whether it 
is based on susceptibility, age group, gender, profession, mobility or 
other categories. This priority scale of groups refers to WHO and the 
Department of Health instructions as the authorized agency to 
determine the category. After that, there is the determination of the 
stages of vaccination because the vaccination was intended for 
various age groups or certain professional groups, such as health 
workers and non-health workers (table 1) [25]. After that, the 
determination of a vaccine was done twice. These steps must be 
decided for the mass vaccination to be done properly and correctly. 
  
Table 1: The stages of Covid-19 vaccination in Indonesia 
Period I: Jan–April 2021 Period II: April 2021–Mar 2022 
 1st 2 Phase nd 3 Phase  rd 4 Phase  th Phase  
Health Workers  




High-risk people of transmission  
Other People 
Based on Cluster depend on vaccine availability  
1.3 Million Elderly 21.5 Million 63.9 Million 77.4 Million 
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After the Indonesian government has decided on a sufficient amount 
of vaccine for the first phase, they consider the challenge of whether 
the vaccine distribution to arrive on time. It is because of the large 
area of Indonesia and the storage process for vaccines that requires 
special handling (cold chain) to maintain the quality of the vaccines. 
The next challenge is about the implementation. Indonesia had 
implemented vaccination for health workers. Follow-up events after 
immunization (KIPI) had been anticipated by all vaccination centers 
with observation post-immunization and offered the contact to be 
called for the post-immunization effect. 
It is important to be understood, as there is no certainty about free 
vaccine or standalone vaccine (paid). According to the plan, this 
information is crucially needed by society to implement mass 
COVID-19 vaccination in the national vaccination program.  
CONCLUSION 
COVID-19 vaccine efficacy study is essential to obtain the safe 
vaccine and to give optimal protection from COVID-19. It is also 
important to hold intensive, continuous and massive socialization 
and campaign in order for society to be understood about the main 
purpose of vaccine implementation. The large area of Indonesia 
must be considered and noticed for the implementer of vaccination 
in the field, especially in logistic storage related to temperature, 
security of distribution track, the proportion of area requirements, 
the number of vaccine officers and other supporting facilities.  
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